Kanada - angielski - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists

Kanada - angielski - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - solution - 25mg - ranitidine (ranitidine hydrochloride) 25mg - histamine h2-antagonists

Kanada - angielski - Health Canada

teva canada limited - ranitidine (ranitidine hydrochloride) - solution - 75mg - ranitidine (ranitidine hydrochloride) 75mg - histamine h2-antagonists

Kanada - angielski - Health Canada

ranbaxy pharmaceuticals canada inc. - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists

Kanada - angielski - Health Canada

ranbaxy pharmaceuticals canada inc. - ranitidine (ranitidine hydrochloride) - tablet - 300mg - ranitidine (ranitidine hydrochloride) 300mg - histamine h2-antagonists

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg - ranitidine tablets, usp is indicated in: 1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

carilion materials management - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 15 mg in 1 ml - ranitidine oral solution is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ranitidine hydrochloride 168mg equivalent to ranitidine 150 mg;   - film coated tablet - 150 mg - active: ranitidine hydrochloride 168mg equivalent to ranitidine 150 mg   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white ys-22-18096 purified water

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ranitidine hydrochloride 336mg equivalent to ranitidine 300 mg;   - film coated tablet - 300 mg - active: ranitidine hydrochloride 336mg equivalent to ranitidine 300 mg   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white ys-22-18096 purified water

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

rebel distributors - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine hydrochloride 150 mg - ranitidine tablets, usp is indicated in: 1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried